Ganga Pharma's FY26 results show modest uptick, no surprises
Revenue rose to ₹282.79 lakhs, net profit to ₹10.15 lakhs; clean audit opinion keeps the filing routine for the nano-cap.
— 1 earlier story on Ganga Pharmaceuticals Ltd. →Mkt cap₹7 cr
P/E89.76×
ROE1.11%
Debt / eq.0.20
₹10.15 lakhs Net profit for FY26, up from ₹7.90 lakhs
What's new with Ganga Pharmaceuticals Ltd.
- Revenue inched up to ₹282.79 lakhs from ₹263.74 lakhs
- Net profit rose 28% to ₹10.15 lakhs from ₹7.90 lakhs
- Auditor issued an unmodified opinion; no profit warnings or guidance changes
Why this matters for Ganga Pharmaceuticals Ltd.
For a nano-cap with a ₹7 crore market cap, these are routine results that carry no market-moving news. The modest improvement and clean audit provide no reason for material share price action.
What we're watching
- Next quarter's revenue trajectory to see if growth sustains
- Any future guidance from management on scaling operations
The full read
Ganga Pharmaceuticals reported a modest uptick in its audited FY26 numbers. Revenue inched up to ₹282.79 lakhs and net profit to ₹10.15 lakhs, both marginally higher than the prior year. The auditor issued a clean opinion. For a company with a market cap just over ₹7 crore, the results are routine and contain no surprises that would move the stock.
Mentioned: FY26 audited results · ₹282.79 lakhs revenue · ₹10.15 lakhs net profit